ProfileGDS5678 / 1416619_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 93% 93% 94% 94% 94% 95% 94% 92% 93% 93% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9876494
GSM967853U87-EV human glioblastoma xenograft - Control 27.9997293
GSM967854U87-EV human glioblastoma xenograft - Control 37.8315393
GSM967855U87-EV human glioblastoma xenograft - Control 48.1150593
GSM967856U87-EV human glioblastoma xenograft - Control 58.0854994
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.0037594
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9768194
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.26395
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.0473194
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.555892
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9175193
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9684193
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6700792
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.783693